Compare TSEM & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | DGX |
|---|---|---|
| Founded | 1993 | 1967 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 23.2B |
| IPO Year | 1996 | 1996 |
| Metric | TSEM | DGX |
|---|---|---|
| Price | $223.08 | $237.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $161.75 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 1.4M | 751.7K |
| Earning Date | 05-13-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 5.08 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $19.21 | $7.53 |
| Revenue Next Year | $26.62 | $3.77 |
| P/E Ratio | $66.16 | ★ $46.74 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $63.54 | $171.18 |
| 52 Week High | $319.94 | $247.19 |
| Indicator | TSEM | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 52.40 |
| Support Level | $184.61 | $232.28 |
| Resistance Level | $274.55 | $240.13 |
| Average True Range (ATR) | 11.22 | 4.80 |
| MACD | -2.65 | -1.44 |
| Stochastic Oscillator | 12.13 | 31.11 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs) based on the design specifications of customers. The company's line of integrated circuits is incorporated into markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.